Education
Health
Chandan Healthcare Scales Franchise Network to 500+ Franchises; Targets 1,000 Franchises by FY27-End
Lucknow (Uttar Pradesh) [India], September 23: Chandan Healthcare Limited (NSE – CHANDAN), – an integrated diagnostics company offering pathology and radiology services, has expanded its diagnostic franchise network to 568 franchises within a short span of six months, strengthening its last-mile presence and diagnostic collection network. The Company plans to scale the network to 1,000 franchises by the end of FY27 and subsequently target 3,000 franchises over the next two years.
Chandan Healthcare’s franchises primarily operate as diagnostic collection points, with samples routed to the nearest Chandan laboratory or diagnostic centre for processing. The franchise partner undertakes local infrastructure and operating expenses, while Chandan provides diagnostic capabilities, quality protocols, branding and operational support. With franchise outlets requiring no capex deployment from Chandan Healthcare, the model enables the Company to scale its network without additional franchise-level capital investment from its balance sheet, while supporting its margin profile.
As on 23rd September, 2026, the Company operates 23 Comprehensive Diagnostic Centres, 18 Diagnostic Centres, 25 standalone laboratories and 2 Central Reference Laboratories, alongside a network of 568 operational franchises.
Currently, around 80% of the franchise network is concentrated in Uttar Pradesh, where Chandan has built significant collection density around its diagnostic infrastructure. The next phase will focus on replicating this network across newer geographies, with the Company progressively expanding its franchise presence across India.
The combination of owned diagnostic hubs and an expanding franchise network provides Chandan Healthcare with a scalable route to enter new markets, widen patient access and generate additional volumes for its existing laboratory infrastructure.
Commenting on the Development, Mr. Amar Singh, Promoter and Chairman & Managing Director of Chandan Healthcare Limited, said, “Our franchise journey is still relatively new, but the response has enabled us to scale to 568 franchises within a short span of six months. We are now working towards reaching 1,000 franchises by the end of FY27 and subsequently scaling the network to 3,000 franchises over the next two years.
The strategy is to build laboratories and diagnostic centres as hubs and create a wider network of franchise collection points around them. This allows us to reach patients in locations where establishing a full diagnostic centre may not be necessary, while the additional sample volumes can improve utilisation of our existing laboratory infrastructure. As our owned and franchise networks expand together, we expect to build a significantly wider diagnostics footprint across India.”
About Chandan Healthcare Limited
Chandan Healthcare Limited, established in 2003, is one of India’s leading providers of diagnostic and pharmacy services and a key entity of the Chandan Group. The Company delivers a comprehensive range of pathology and radiology services through its expanding network across India.
As on 23rd September 2026, the Company operates 568 Franchise, 23 Comprehensive Diagnostic Centres, 18 Diagnostic Centres, 25 standalone laboratories, 2 Central Reference Laboratories, strengthening its presence across urban, semi-urban and emerging markets. Its diagnostic portfolio comprises more than 3,000 pathology tests and 500+ radiology tests, including blood tests, X-ray, ECG, Ultrasound, CT scan, MRI and several other specialized diagnostic investigations. The Company’s network includes NABL and NABH accredited pathology laboratories and radiology centres, reflecting its commitment to delivering reliable, high-quality diagnostic services.
Chandan Healthcare operates through a diversified business model comprising B2C (Retail Customers), B2B (Institutional & Corporate Clients) and B2G (Government PPP Contracts), providing a balanced and scalable revenue profile while catering to a wide spectrum of healthcare needs.
The Company was listed on the NSE Emerge platform on February 17, 2025.
During FY26, The Company reported Consolidated Total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr and Profit After Tax (PAT) of ₹27.06 Cr, reflecting its continued operational growth and financial strength.
Disclaimer: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
Business
Liquide’s Draws 1,500+ Seasoned Traders to Conclave 5.0 as AI Reshapes India’s Trading Landscape
Left to Right: Kunal Ambasta – CIO & Co-Founder, Paritosh Gunjan – CTO & Co-Founder, Anuj Bajpai – CEO & Co-Founder
Bengaluru (Karnataka) [India], September 28: Liquide Solutions, India’s leading AI-led equity research and trading platform, concluded the fifth edition of Traders Conclave on September 18 at the MLR Convention Centre in Whitefield, Bengaluru, bringing together more than 1,500 paid attendees, alongside market experts, financial platforms, technology companies and investors.
The turnout reflects a broader shift underway in India’s stock trading ecosystem: retail traders and stock investors are increasingly looking beyond access to markets toward better research, intelligence and technology to support their investment decisions.
For Liquide, which is building an AI-powered investing and trading platform for Indian retail users, Traders Conclave has evolved into a physical extension of the community it serves digitally—bringing investors, traders, market leaders and technology platforms together around the future of investing.
AI Moves to the Centre of the Trading Experience
AI emerged as a defining theme at Traders Conclave 5.0, reshaping how investors research markets, analyse portfolios and process information at speed. Liquide is at the forefront of this shift with LiMo, its AI-powered research assistant bringing institutional-grade market intelligence within reach of individual investors.
Led by Liquide’s Founder & CEO Anuj Bajpai, the conclave featured a marquee leadership panel with Dale Vaz, Founder & CEO of SAHI; Nikhil Behl, Co-Founder & CEO of INDmoney Broking; and Devam Sardana, Business Head at Lemonn. The leaders discussed the future of Indian wealthtech and how AI is transforming research, execution and access to global markets, while enabling more informed investor decisions.
“Technology can make traders faster, and AI can make them smarter, but communities make the journey better. That is the idea behind Traders Conclave. Markets will always change, and when they do, having a strategy matters more than having a prediction. At Liquide, our role is to support investors through research, technology and education, so that more people can participate in the markets with greater clarity and awareness,” said Anuj Bajpai, Founder & CEO of Liquide.
From Predictions to Disciplined Decision-Making
Across sessions on trading strategies, derivatives, market volatility, asset allocation, risk management, investor behaviour and emerging asset classes, one idea repeatedly surfaced: better investing is less about predicting every market move and more about building disciplined decision-making systems.
Speakers discussed how AI, data and analytical tools can help investors process information faster, understand risk more clearly and apply greater structure to investment decisions—while keeping human judgement at the centre.
This shift from information access to decision intelligence is also shaping Liquide’s product direction as it builds technology spanning research, portfolio analytics, investment insights and investor education.
A Growing Ecosystem Around the Indian Traders
Traders Conclave 5.0 also brought together companies from across India’s fast-evolving investing ecosystem, including SAHI, FYERS and Motilal Oswal, alongside platforms such as Delta Exchange, Mudrex and Coinbase.
Product showcases and partner interactions allowed attendees to experience trading platforms, analytical tools and new technologies directly, connecting conversations on stage with practical applications across investing and trading.
The diversity of participating companies reflected how rapidly the boundaries of wealthtech are expanding—from traditional equities and derivatives to AI-led research, global markets, alternative assets and new investing infrastructure.
1,500+ Paid Attendees: Community as a Distribution Advantage
Unlike passive digital audiences, Traders Conclave is built around high-intent participation. More than 1,500 people bought paid passes to attend the Bengaluru edition, spending a full day learning, exchanging strategies and interacting with market practitioners and technology platforms.
For Liquide, the community represents more than an annual event. It forms part of a broader ecosystem connecting its technology, research, education and investor engagement.
About Liquide
Liquide Solutions is a SEBI-registered Research Analyst (Registration No. INH000009816) building an AI-powered stock research and trading platform for Indian investors. With 6 million+ downloads and $6 Million in assets under advisory, Liquide is building an AI-native wealth platform for India’s growing retail and mass-affluent retail trader base.
At the centre of the platform is LiMo, Liquide’s AI-powered investment research assistant, which works alongside portfolio analytics, expert-led research, curated investment strategies and investor education to help users understand markets and make more informed investment decisions.
Liquide is building toward a future where sophisticated investment intelligence – historically available primarily to professional and institutional investors – becomes accessible to millions of individual investors through AI.
For more information, visit www.liquide.life or contact [email protected].
If you object to the content of this press release, please notify us at [email protected]. We will respond and rectify the situation within 24 hours.
